Log in
Sheila Ellwood (at Bristol from 2006) examined how managerial freedoms created through the trend to decentralise public service organisations need to be tempered through `better' accounting. Her research has led to her appointment as a non executive director (2000-2005) and a Treasury Panel member (2009-11). The research impacts on both national policy and local financial management. Her impact is seen in the financial reporting policy in local public bodies; the policy on auditing local public bodies and in the costing/ pricing of healthcare. Her work has been used in UK parliamentary committees and incorporated into government accounting manuals. International recognition includes dissemination of her work by the Chinese Treasury.
Unique research at the University of Manchester highlights the shortcomings of public accountability and the high cost, to the public purse, of PPPs and the Private Finance Initiative (PFI) using critical financial analysis. Lead researchers have been invited to engage in dialogue with national audit regulators, give evidence to parliamentary committees and contribute to policy debate through international roundtables. The work has been used to challenge government policy and has significantly influenced the national and international public debate about the costs, affordability and value for money of PPPs. The UK government has now renegotiated existing PFI projects to achieve cost savings, and we have given evidence by invitation to international committees concerned with public accountability and policy development.
Research at UCL by Edkins, Ive et al, commencing in 1996, into the Private Finance Initiative (PFI) and Public Private Partnership (PPP) has resulted in an independent and objective commentary on the use and practicalities of this procurement framework. It has also led to the development of training courses and reusable training materials for practitioners and the development of advocacy networks to influence policy-makers and wider discourse about PFI in the UK, New Zealand and beyond. As a result, UCL research has improved PFI/PPP guidance and training, and enhanced practitioners' abilities to deliver PFI projects, whilst analysis of project operations has informed the development of PFI as a continuing form of government procurement.
The NHS spends about £11bn annually on pharmaceuticals, of which £8bn is on branded drugs, representing about 13% and 10% respectively of available NHS resources. Research at York has been central to the public and policy debate about how branded pharmaceuticals ought to be priced and has made a material contribution to the development of government policy to introduce a value based pricing (VBP) scheme for all new pharmaceuticals. VBP has significance for the prices that the NHS pays for pharmaceuticals, access to new drugs for NHS patients, and the return that manufacturers can expect from future research and development. There is also an international impact in two respects: UK prices are estimated to influence 25% of the world market and York has contributed to a wider policy debate about international pharmaceutical pricing and the potential role of value based pricing in European, North American, South American and South East Asian health care systems.
Professor Robin Blackburn has written extensively on pension policy and has advocated the need for strong public pension provision. Following the financial crisis that began in 2008, Blackburn's ideas have attracted much interest, especially given that he had identified many of the problems that would come to afflict private schemes. His work has been recognised globally: for example, he was invited to speak at a conference organised by the EU Commissioner for Employment, Social Affairs and Inclusion, and his research has been cited by the United Nations' Department of Economic and Social Affairs. Blackburn's highest-profile work has been in Ecuador, where he has addressed the President, cabinet ministers, and senior civil servants.
Professor Paul Grout has had a significant impact on national policy on the delivery of public services by the private sector in the last five years. His research undertaken at the University of Bristol on private provision by regulated utility companies and public private partnerships, using both economic theory and empirical studies, paved the way for his central involvement in, and directly informed, key regulatory decisions. These decisions impact materially on almost every individual and organisation in the UK. His research also directly led to his appointment in 2012 to the Board of Ofgem (the Gas and Electricity Markets Authority), the UK energy regulator.
Methods developed at the University of York for measuring NHS productivity have changed how the Office of National Statistics values the NHS in the national accounts. Our methods, which take into account improvements in the quality of care, have been incorporated into submissions to the Comprehensive Spending Reviews that determine the NHS budget and are internationally influential. Research on productivity at hospital level has influenced the tariffs set by the Department of Health for reimbursement of specialist hospital care. Research on the productivity of hospital consultants influenced the reviews of doctors' pay and rewards by the Doctors' and Dentists' Pay Review Body and the National Audit Office and formed the basis of benchmarking tools distributed for use in the NHS.
Research on the effects of organizational autonomy in the NHS was conducted at Royal Holloway between 2006 and 2009, and has informed debates that have contributed to policy and practitioner decision-making. Through qualitative methods, it examined the impact of autonomy (from central government) upon local decision-making in NHS organisations. The work explained why the number of Foundation Trusts (FTs) established had not risen in line with the Department of Health's expectations, which originally sought to make all NHS Trusts become FTs. It also explained why FTs were not willing to exercise their autonomy despite being able to do so. The research has influenced policy debate and decision-making within the Department of Health, Monitor (the FT regulator), and the wider NHS.